Literature DB >> 16126463

Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.

Brian T Feeley1, Lucie Krenek, Nancy Liu, Wellington K Hsu, Seth C Gamradt, Edward M Schwarz, Johnny Huard, Jay R Lieberman.   

Abstract

INTRODUCTION: Although a majority of metastatic prostate cancer lesions are osteoblastic in nature, some are mixed or lytic; and, osteoblastic lesions require osteolytic activity in order to progress. The role of BMPs in the formation of prostate cancer metastases to bone remains unknown. We hypothesized that BMPs influence the development and progression of osteolytic prostate cancer lesions.
METHODS: RT-PCR and Western blot analysis were used to determine BMP receptor expression on the osteolytic prostate cancer cell line PC-3. Migration, invasion, and cellular proliferation assays were performed on PC-3 cells to quantify the effects of BMP-2, -4, and -7. In vivo, PC-3 cells were injected alone, with an empty retroviral vector, or with a retroviral vector overexpressing noggin, into the tibias of SCID mice. The animals were followed for 8 weeks, and histologic and radiographic analysis were performed at 2, 4, 6, and 8 weeks.
RESULTS: BMP receptors are expressed on PC-3 cells, suggesting that they would be responsive to host BMP secretion. BMP-2, and to a lesser extent, BMP-4, stimulated PC-3 cell migration and invasion in a dose-dependent fashion. Noggin inhibited cellular migration and invasion of BMP-2 and -4 stimulated PC-3 cells. BMP-2 alone stimulated PC-3 cell proliferation, but BMP-4 had no effect. BMP-7 had no effect on proliferation, migration, or invasion. PC-3 cells implanted into SCID mouse tibias formed osteolytic lesions as early as 2 weeks and completely destroyed the proximal tibia by 8 weeks. Overexpression of noggin in PC-3 cells inhibited the expansion of the lesion in vivo.
CONCLUSIONS: BMPs influence the formation of the osteolytic prostate cancer metastases, and treatment modalities that inhibit BMP activity may limit the progression of the lytic component of prostate cancer metastases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126463     DOI: 10.1016/j.bone.2005.07.015

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  54 in total

1.  Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Authors:  Dan Guo; Jiayi Huang; Jianping Gong
Journal:  Mol Cell Biochem       Date:  2011-12-14       Impact factor: 3.396

2.  Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Authors:  Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman
Journal:  Bone       Date:  2010-11-10       Impact factor: 4.398

Review 3.  Nothing but skin and bone.

Authors:  F Patrick Ross; Angela M Christiano
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

4.  Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals.

Authors:  Hikaru Nishimori; Shogo Ehata; Hiroshi I Suzuki; Yoko Katsuno; Kohei Miyazono
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

5.  Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

Authors:  Ruth Schwaninger; Cyrill A Rentsch; Antoinette Wetterwald; Geertje van der Horst; Rutger L van Bezooijen; Gabri van der Pluijm; Clemens W G M Löwik; Karin Ackermann; Walter Pyerin; Freddie C Hamdy; George N Thalmann; Marco G Cecchini
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

6.  BMP7: a new bone metastases prevention?

Authors:  Pierrick G J Fournier; Theresa A Guise
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

7.  Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Authors:  Linda Kim Pham; Mengmeng Liang; Helty A Adisetiyo; Chun-Peng Liao; Michael B Cohen; Stanley M Tahara; Baruch Frenkel; Noriyuki Kasahara; Pradip Roy-Burman
Journal:  Endocr Relat Cancer       Date:  2013-11-04       Impact factor: 5.678

Review 8.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Authors:  Pawina Jiramongkolchai; Philip Owens; Charles C Hong
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

9.  Co-evolution of breast-to-brain metastasis and neural progenitor cells.

Authors:  Josh Neman; Cecilia Choy; Claudia M Kowolik; Athena Anderson; Vincent J Duenas; Sarah Waliany; Bihong T Chen; Mike Y Chen; Rahul Jandial
Journal:  Clin Exp Metastasis       Date:  2013-02-28       Impact factor: 5.150

10.  The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients.

Authors:  Xiangshan Yang; Daotang Li; Shaomei Cheng; Kaixi Fan; Lijun Sheng; Jing Zhang; Bin Feng; Zhongfa Xu
Journal:  Tumour Biol       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.